Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

Emre M., Tsolaki M., Bonuccelli U., Destee A., Tolosa E., Kutzelnigg A., ...Daha Fazla

LANCET NEUROLOGY, cilt.9, sa.10, ss.969-977, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 10
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/s1474-4422(10)70194-0
  • Dergi Adı: LANCET NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.969-977
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Background Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB).